These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
461 related articles for article (PubMed ID: 27672299)
1. Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12. Werner CR; Schwarz JM; Egetemeyr DP; Beck R; Malek NP; Lauer UM; Berg CP World J Gastroenterol; 2016 Sep; 22(35):8050-9. PubMed ID: 27672299 [TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation. Beinhardt S; Al-Zoairy R; Kozbial K; Stättermayer AF; Maieron A; Stauber R; Strasser M; Zoller H; Graziadei I; Rasoul-Rockenschaub S; Trauner M; Ferenci P; Hofer H Liver Int; 2018 Jul; 38(7):1188-1197. PubMed ID: 29197145 [TBL] [Abstract][Full Text] [Related]
3. Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience. Pillai AA; Wedd J; Norvell JP; Parekh S; Cheng N; Young N; Spivey JR; Ford R Am J Gastroenterol; 2016 Feb; 111(2):250-60. PubMed ID: 26832650 [TBL] [Abstract][Full Text] [Related]
4. Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment. Aqel B; Leise M; Vargas HE; Watt KD; Keaveny AP; Zhang N; Zhang N; Pungpapong S Ann Hepatol; 2018 Aug; 17(5):815-821. PubMed ID: 30145562 [TBL] [Abstract][Full Text] [Related]
5. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Fontana RJ; Brown RS; Moreno-Zamora A; Prieto M; Joshi S; Londoño MC; Herzer K; Chacko KR; Stauber RE; Knop V; Jafri SM; Castells L; Ferenci P; Torti C; Durand CM; Loiacono L; Lionetti R; Bahirwani R; Weiland O; Mubarak A; ElSharkawy AM; Stadler B; Montalbano M; Berg C; Pellicelli AM; Stenmark S; Vekeman F; Ionescu-Ittu R; Emond B; Reddy KR Liver Transpl; 2016 Apr; 22(4):446-58. PubMed ID: 26890629 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease. Moser S; Kozbial K; Laferl H; Schütz A; Reiberger T; Schwabl P; Gutic E; Schwanke C; Schubert R; Luhn J; Lang T; Schleicher M; Steindl-Munda P; Haltmayer H; Ferenci P; Gschwantler M Eur J Gastroenterol Hepatol; 2018 Mar; 30(3):291-295. PubMed ID: 29120906 [TBL] [Abstract][Full Text] [Related]
7. DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting. Beinhardt S; Al Zoairy R; Ferenci P; Kozbial K; Freissmuth C; Stern R; Stättermayer AF; Stauber R; Strasser M; Zoller H; Watschinger B; Schmidt A; Trauner M; Hofer H; Maieron A Transpl Int; 2016 Sep; 29(9):999-1007. PubMed ID: 27203857 [TBL] [Abstract][Full Text] [Related]
8. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin. Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544 [TBL] [Abstract][Full Text] [Related]
10. Direct-acting antiviral regimens in Egyptian patients with chronic hepatitis C virus infection: A real-world single-center experience. Naguib GG; Farid A; Hassan M; Elshafie A; Shazly YE; Shaker MK; Ezzat H; Safwat E; Ahmed OA; Dabbous H; Sherief AF; Hassany M; Elserafy M; Elsayed MH Arab J Gastroenterol; 2021 Dec; 22(4):285-291. PubMed ID: 34531135 [TBL] [Abstract][Full Text] [Related]
11. Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus. Rupp C; Hippchen T; Neuberger M; Sauer P; Pfeiffenberger J; Stremmel W; Gotthardt DN; Mehrabi A; Weiss KH World J Gastroenterol; 2018 Mar; 24(12):1353-1360. PubMed ID: 29599610 [TBL] [Abstract][Full Text] [Related]
12. Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil. Lobato CMO; Codes L; Silva GF; Souza AFM; Coelho HSM; Pedroso MLA; Parise ER; Lima LMSTB; Borba LA; Evangelista AS; Rezende REF; Cheinquer H; Kuniyoshi ASO; Aires RS; Quintela EHD; Mendes LSC; Nascimento FCV; Medeiros Filho JEM; Ferraz MLCG; Abdala E; Bittencourt PL; ; Ann Hepatol; 2019; 18(6):849-854. PubMed ID: 31537509 [TBL] [Abstract][Full Text] [Related]
13. Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES. Butt AA; Yan P; Shaikh OS; Chung RT; Sherman KE; Liver Int; 2016 Sep; 36(9):1275-83. PubMed ID: 26928927 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort. Alonso S; Riveiro-Barciela M; Fernandez I; Rincón D; Real Y; Llerena S; Gea F; Olveira A; Fernandez-Carrillo C; Polo B; Carrión JA; Gómez A; Devesa MJ; Baliellas C; Castro Á; Ampuero J; Granados R; Pascasio JM; Rubín A; Salmeron J; Badia E; Planas JM; Lens S; Turnes J; Montero JL; Buti M; Esteban R; Fernández-Rodríguez CM J Viral Hepat; 2017 Apr; 24(4):304-311. PubMed ID: 27935168 [TBL] [Abstract][Full Text] [Related]
15. Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study. Dalgard O; Weiland O; Noraberg G; Karlsen L; Heggelund L; Färkkilâ M; Balslev U; Belard E; Øvrehus A; Skalshøi Kjær M; Krarup H; Thorup Røge B; Hallager S; Madsen LG; Lund Laursen A; Lagging M; Weis N PLoS One; 2017; 12(7):e0179764. PubMed ID: 28704381 [TBL] [Abstract][Full Text] [Related]
16. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Reddy KR; Bourlière M; Sulkowski M; Omata M; Zeuzem S; Feld JJ; Lawitz E; Marcellin P; Welzel TM; Hyland R; Ding X; Yang J; Knox S; Pang P; Dvory-Sobol H; Subramanian GM; Symonds W; McHutchison JG; Mangia A; Gane E; Mizokami M; Pol S; Afdhal N Hepatology; 2015 Jul; 62(1):79-86. PubMed ID: 25846144 [TBL] [Abstract][Full Text] [Related]
17. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. Aqel BA; Pungpapong S; Leise M; Werner KT; Chervenak AE; Watt KD; Murphy JL; Ryland K; Keaveny AP; McLemore R; Vargas HE Hepatology; 2015 Oct; 62(4):1004-12. PubMed ID: 26096332 [TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-based retrospective cohort study. Gayam V; Tiongson B; Khalid M; Mandal AK; Mukhtar O; Gill A; Garlapati P; Shrestha B; Khalid M; Chakraborty S; Guss D; Sherigar J; Mansour M; Mohanty S Eur J Gastroenterol Hepatol; 2018 Oct; 30(10):1200-1207. PubMed ID: 30096090 [TBL] [Abstract][Full Text] [Related]
19. Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study. Lionetti R; Calvaruso V; Piccolo P; Mancusi RL; Mazzarelli C; Fagiuoli S; Montalbano M; Lenci I; Carrai P; Guaraldi G; Visco-Comandini U; Milana M; Biolato M; Loiacono L; Valente G; Craxì A; Angelico M; D'offizi G Clin Transplant; 2018 Feb; 32(2):. PubMed ID: 29193356 [TBL] [Abstract][Full Text] [Related]
20. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease. García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]